X
[{"orgOrder":0,"company":"Amazentis","sponsor":"Scripps Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Shows Urolithin A (Mitopure\u00ae) Improves Mitochondrial Health, Reduces Joint Cartilage Damage and Alleviates Pain in Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Amazentis"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Adge Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adge Pharmaceuticals Secures License To Evaluate Two New Programs In Rare Pediatric Diseases","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"F. Hoffmann-La Roche"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
Mitopure® is a highly pure form of Urolithin A; a bioactive dietary metabolite that is produced by gut bacteria after eating certain foods, such as the pomegranate, though it is difficult for most people to get enough of this specialized nutrient from food alone.
Lead Product(s):
Urolithin A
Therapeutic Area: Musculoskeletal
Product Name: Mitopure
Highest Development Status: Preclinical
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Scripps Research
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 07, 2022
Details:
Adge Pharmaceuticals has in-licensed RO269228, a clinical stage oral small molecule, for the treatment of Rett syndrome and Osteogenesis imperfecta and potentially other indications with unmet medical needs.
Lead Product(s):
Elocalcitol
Therapeutic Area: Musculoskeletal
Product Name: RO269228
Highest Development Status: Preclinical
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Adge Pharmaceuticals
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
March 22, 2022